Janice Olson

Corporate Officer/Principal at LOGICBIO THERAPEUTICS, INC.

Health Technology

Consumer Services

Profile

Janice Olson is currently the Senior VP-Strategy & Portfolio Management at LogicBio Therapeutics, Inc. She previously worked as the Head-Global Medical Affairs Operations at Genzyme Corp.
Olson received her undergraduate degree and MBA from Northeastern University.

Janice Olson active positions

Companies	Position	Start
LOGICBIO THERAPEUTICS, INC.	Corporate Officer/Principal	2021-06-06

All active positions of Janice Olson

Former positions of Janice Olson

Companies	Position	End
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-

See the detail of Janice Olson's experience

Training of Janice Olson

Northeastern University

Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Janice Olson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Health Technology
LogicBio Therapeutics, Inc. LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.	Health Technology